When Trova Wine and Market shut its doors last month after nearly five years in business in Dallas, owner Michelle Bonds pointed to an unexpected reason for closure: GLP-1 weight loss drugs like ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. Diabetes, a ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

They're known to aid in blood sugar control and, now, weight loss — however, according to a sweeping new study, the popular ...

“While they act through different biochemical pathways, both GLP-1 agonists and SGLT2 inhibitors have been shown to decrease the risk of cardiovascular disease. They both likely accomplish this by ...